Moody’s: Valeant unchanged by amendment

Moody's Investors Service said that a proposed amendment to Valeant Pharmaceuticals International Inc.'s credit agreement will improve its liquidity position due to increased cushion under financial maintenance covenants.

There is no impact on Valeant's ratings, including the B2 corporate family rating and the negative outlook.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.